Sugentech Establishes Allergy Testing Solution Covering 239 Allergens
Sugentech, a global in vitro diagnostics company, has built Korea's largest allergy testing solution, covering 239 allergens.
Sugentech announced on October 29 that it had obtained domestic regulatory approval for its new allergy diagnostic product, 'SGTi-Allergy PLUS 120.'
The newly approved product can offer tests for up to 239 allergens when used alongside the existing 'SGTi-Allergy Screen PLUS.' It can test for a wide range of allergy triggers encountered in Korea and abroad, including inhalant, environmental, and food allergens. Analysis of 45 component allergens also allows for more detailed assessment of allergy sensitization.
Building on this, Sugentech plans to target the European market. The company is pursuing CE certification under the European Union's In Vitro Diagnostic Medical Devices Regulation (IVDR) and expects to obtain approval by the end of this year. It plans to use this as a springboard to register its products in major European countries and expand its local distribution network, strengthening its export competitiveness in the global allergy diagnostics market.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Sugentech official said, "This approval for our new product will be an important opportunity to expand our allergy diagnostics business, backed by Korea's broadest testing range of 239 allergens and our in-house expertise in developing equipment and reagents. We will expand supply to major domestic reference laboratories and large hospitals, and accelerate global business growth in 2027 by leveraging our experience in overseas markets, including Asia and Africa, and obtaining IVDR approval in Europe by the end of this year."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.